Literature DB >> 15846442

Advances in the surgical treatment of fecal incontinence.

Benjamin Person1, Steven D Wexner.   

Abstract

Although surgery for fecal incontinence has been shown to be effective, it is still very challenging and sometimes frustrating. Overlapping sphincteroplasty, by far the most common procedure, is effective in patients with sphincter defects; however, recent data suggest that success rates tend to deteriorate over time. A thorough preoperative evaluation incorporates numerous factors, including patient characteristics, severity of incontinence, type and size of the sphincter defect as assessed by physical examination, anal ultrasound, and anorectal physiology studies including anal manometry, electromyography, and pudendal nerve terminal motor latency assessment. The use of these evaluation methods has allowed better patient assignment for a variety of new alternative treatment options. Innovations in the surgical treatment of fecal incontinence range from simple, office-based sphincter augmentation techniques to surgical implantation of mechanical devices. This article reviews 5 alternative surgical treatment options for fecal incontinence: injection of carbon-coated beads in the submucosa of the anal canal, radiofrequency energy delivery, stimulated graciloplasty, artificial bowel sphincter, and sacral nerve stimulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846442     DOI: 10.1177/155335060501200103

Source DB:  PubMed          Journal:  Surg Innov        ISSN: 1553-3506            Impact factor:   2.058


  1 in total

1.  Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence.

Authors:  Steven D Wexner; Tracy Hull; Yair Edden; John A Coller; Ghislain Devroede; Richard McCallum; Miranda Chan; Jennifer M Ayscue; Abbas S Shobeiri; David Margolin; Michael England; Howard Kaufman; William J Snape; Ece Mutlu; Heidi Chua; Paul Pettit; Deborah Nagle; Robert D Madoff; Darin R Lerew; Anders Mellgren
Journal:  J Gastrointest Surg       Date:  2010-03-31       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.